UniQure has applied for a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease.
The company also announced that its Marketing Authorisation Application (MAA) for ifezuntirgene inilparvovec has been submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
The company has requested priority review for the BLA. If granted, priority review would shorten the FDA review cycle to six months following the FDA’s 60-day BLA filing review period.
The BLA and MAA are supported by the previously announced three-year data analysis from the phase 1/2 clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database. The company intends to present a four-year data analysis from the ongoing phase 1/2 clinical studies before the end of the current third quarter.
Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received breakthrough therapy and regenerative medicine advanced therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds fast track designation from the FDA.
